Emergent Biosolutions (EBS)

• Market cap: $450M
• 1 day: 1.84%
• 5 days: -6.32%
• 1 month: -15.74%
• 3 months: 35.84%
• 6 months: 22.60%
• Year to date: 220.46%
• 1 year: 244.40%
• 5 years: -85.14%
• 10 years: -69.97%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Employees: 1,600

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

22% more capital invested

Capital invested by funds: $216M [Q2] → $265M (+$48.5M) [Q3]

0.04% more ownership

Funds ownership: 60.43% [Q2] → 60.47% (+0.04%) [Q3]

1% less funds holding

Funds holding: 141 [Q2] → 140 (-1) [Q3]

3% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 34

11% less call options, than puts

Call options by funds: $7.37M | Put options by funds: $8.31M

40% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 50

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12 45% upside
• Avg. target: $12 45% upside
• High target: $12 45% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Benchmark Robert Wasserman 52% 1-year accuracy 26 / 50 met price target

45% upside $12

Buy Maintained

7 Nov 2024